• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人类对脑膜炎球菌的免疫力。IV. A群和C群脑膜炎球菌多糖对人类志愿者的免疫原性。

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

作者信息

Gotschlich E C, Goldschneider I, Artenstein M S

出版信息

J Exp Med. 1969 Jun 1;129(6):1367-84. doi: 10.1084/jem.129.6.1367.

DOI:10.1084/jem.129.6.1367
PMID:4977283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2138657/
Abstract

High molecular weight group A and group C meningococcal polysaccharides had no significant toxicity for mice or guinea pigs. Furthermore, these polysaccharide preparations contained negligible amounts of biologically active endotoxin. The high molecular weight group A and group C meningococcal polysaccharides were excellent immunogens in six human volunteers. Antibodies belonging to the immunoglobulin classes IgG, IgM, and IgA were produced. These antibodies were highly meningococcocidal in the presence of complement.

摘要

高分子量A群和C群脑膜炎球菌多糖对小鼠或豚鼠无明显毒性。此外，这些多糖制剂中生物活性内毒素的含量可忽略不计。高分子量A群和C群脑膜炎球菌多糖对6名人类志愿者是优良的免疫原。产生了属于免疫球蛋白类IgG、IgM和IgA的抗体。在补体存在的情况下，这些抗体具有高度的杀脑膜炎球菌活性。

相似文献

1
Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.人类对脑膜炎球菌的免疫力。IV. A群和C群脑膜炎球菌多糖对人类志愿者的免疫原性。
J Exp Med. 1969 Jun 1;129(6):1367-84. doi: 10.1084/jem.129.6.1367.
2
Immunogenicity of the group A and group C meningococcal polysaccharides in children.A群和C群脑膜炎球菌多糖对儿童的免疫原性
J Infect Dis. 1972 May;125(5):509-19. doi: 10.1093/infdis/125.5.509.
3
Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.B群脑膜炎球菌多糖与2型外膜蛋白复合物在人体中具有免疫原性。
J Clin Invest. 1979 May;63(5):836-48. doi: 10.1172/JCI109383.
4
Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.人类对脑膜炎球菌的免疫力。3. A 群、B 群和 C 群脑膜炎球菌多糖的制备及免疫化学性质。
J Exp Med. 1969 Jun 1;129(6):1349-65. doi: 10.1084/jem.129.6.1349.
5
Standardization and control of meningococcal vaccines, group A and group C polysaccharides.A群和C群脑膜炎球菌多糖疫苗的标准化与控制
J Biol Stand. 1977;5(3):197-215. doi: 10.1016/s0092-1157(77)80005-x.
6
Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.补体来源在人源抗体及抗B群脑膜炎球菌多糖鼠单克隆抗体杀菌活性中的重要性
Infect Immun. 1983 Apr;40(1):257-64. doi: 10.1128/iai.40.1.257-264.1983.
7
Immunological investigations of meningococcal disease. II. Some characteristics of group C antigen of Neisseria meningitidis in the sera of patients with fulminant meningococcemia.脑膜炎球菌病的免疫学研究。II.暴发性脑膜炎球菌血症患者血清中脑膜炎奈瑟菌C群抗原的一些特征。
J Infect Dis. 1974 May;129(5):538-44. doi: 10.1093/infdis/129.5.538.
8
Human immunity to the meningococcus. II. Development of natural immunity.人类对脑膜炎球菌的免疫力。II. 自然免疫力的发展
J Exp Med. 1969 Jun 1;129(6):1327-48. doi: 10.1084/jem.129.6.1327.
9
Latex agglutination test for measurement of antibodies to meningococcal polysaccharides.用于检测抗脑膜炎球菌多糖抗体的乳胶凝集试验。
Infect Immun. 1972 Mar;5(3):346-51. doi: 10.1128/iai.5.3.346-351.1972.
10
Modification of meningococcal polysaccharide antigens for use in passive hemagglutination tests.用于被动血凝试验的脑膜炎球菌多糖抗原的修饰
J Immunol. 1968 Oct;101(4):808-9.

引用本文的文献

1
Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022.利用实时基因组监测数据评估 2015 至 2022 年在苏格兰接种 4CMenB 脑膜炎球菌疫苗的效果。
mBio. 2023 Apr 25;14(2):e0049923. doi: 10.1128/mbio.00499-23. Epub 2023 Apr 10.
2
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.抗击传染病的军事医学策略历史回顾：从战场到全球健康
Biomedicines. 2022 Aug 22;10(8):2050. doi: 10.3390/biomedicines10082050.
3
Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa.A群脑膜炎球菌结合疫苗MenAfriVac在撒哈拉以南非洲预防复发性脑膜炎流行中的效力和效果
Vaccines (Basel). 2022 Apr 14;10(4):617. doi: 10.3390/vaccines10040617.
4
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.抗击侵袭性脑膜炎球菌病的十年：关于MenACWY-CRM结合疫苗临床及实际应用经验的叙述性综述
Infect Dis Ther. 2022 Apr;11(2):639-655. doi: 10.1007/s40121-021-00519-2.
5
Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.采用药物化学方法发现针对细菌性感染的半合成和全合成碳水化合物疫苗。
Chem Rev. 2021 Apr 14;121(7):3598-3626. doi: 10.1021/acs.chemrev.0c01210. Epub 2021 Apr 1.
6
Herd Protection against Meningococcal Disease through Vaccination.通过疫苗接种实现群体对脑膜炎球菌病的保护。
Microorganisms. 2020 Oct 28;8(11):1675. doi: 10.3390/microorganisms8111675.
7
Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis.脑膜炎奈瑟菌：利用基因组学了解多样性、进化和发病机制。
Nat Rev Microbiol. 2020 Feb;18(2):84-96. doi: 10.1038/s41579-019-0282-6. Epub 2019 Nov 8.
8
Vaccine Development and Collaborations: Lessons from the History of the Meningococcal A Vaccine (1969-73).疫苗研发与合作：来自A群脑膜炎球菌疫苗历史（1969 - 1973年）的经验教训
Med Hist. 2019 Oct;63(4):435-453. doi: 10.1017/mdh.2019.43.
9
A preliminary study on the application of PspA as a carrier for group A meningococcal polysaccharide.PspA 作为 A 群脑膜炎球菌多糖载体的初步研究
PLoS One. 2019 Jul 10;14(7):e0218427. doi: 10.1371/journal.pone.0218427. eCollection 2019.
10
Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Isolated from 2009 to 2013 in the Republic of Ireland.爱尔兰共和国 2009 至 2013 年分离的侵袭性 B 群血清型 4CMenB 疫苗的潜在覆盖范围。
mSphere. 2018 Aug 22;3(4):e00196-18. doi: 10.1128/mSphere.00196-18.

本文引用的文献

1
STUDIES ON MENINGOCOCCAL INFECTION : XIII. CORRELATION BETWEEN ANTIPOLYSACCHARIDE AND THE ANTIBODY WHICH PROTECTS MICE AGAINST INFECTION WITH TYPE I MENINGOCOCCI.关于脑膜炎球菌感染的研究：十三. 抗荚膜多糖与保护小鼠免受 I 型脑膜炎球菌感染的抗体之间的相关性。
J Exp Med. 1945 Jan 1;81(1):85-92. doi: 10.1084/jem.81.1.85.
2
CHEMICAL STUDIES ON BACTERIAL AGGLUTINATION : VII. A QUANTITATIVE STUDY OF THE TYPE SPECIFIC AND GROUP SPECIFIC ANTIBODIES IN ANTIMENINGOCOCCAL SERA OF VARIOUS SPECIES AND THEIR RELATION TO MOUSE PROTECTION.细菌凝集的化学研究：VII. 不同种属抗脑膜炎球菌血清中与小鼠保护作用有关的类特异性和群特异性抗体的定量研究。
J Exp Med. 1945 Jan 1;81(1):1-8. doi: 10.1084/jem.81.1.1.
3
PREPARATION OF THE TYPE-SPECIFIC POLYSACCHARIDE OF THE TYPE I MENINGOCOCCUS AND A STUDY OF ITS EFFECTIVENESS AS AN ANTIGEN IN HUMAN BEINGS.制备 I 型脑膜炎奈瑟菌的特异性多糖及其作为人类抗原的有效性研究。
J Exp Med. 1944 Oct 1;80(4):299-307. doi: 10.1084/jem.80.4.299.
4
The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus.人体对同时注射六种肺炎球菌特异性多糖的抗体反应。
J Exp Med. 1948 Sep 1;88(3):369-72. doi: 10.1084/jem.88.3.369.
5
EXPERIMENTAL MENINGOCOCCAL INFECTION IN MICE.小鼠实验性脑膜炎球菌感染
Science. 1933 Oct 13;78(2024):340-1. doi: 10.1126/science.78.2024.340.
6
PERTUSSIS VACCINE TESTING FOR FREEDOM-FROM-TOXICITY.百日咳疫苗无毒性检测
Appl Microbiol. 1965 May;13(3):447-56. doi: 10.1128/am.13.3.447-456.1965.
7
Studies on an endotoxin of a group C Neisseria meningitidis.关于C群脑膜炎奈瑟菌一种内毒素的研究。
J Immunol. 1963 Feb;90:312-7.
8
A defined agar medium for genetic transformation of Neisseria meningitidis.一种用于脑膜炎奈瑟菌基因转化的特定琼脂培养基。
J Bacteriol. 1962 Mar;83(3):470-4. doi: 10.1128/jb.83.3.470-474.1962.
9
The effect of bacterial endotoxins on the water intake and body weight of mice.细菌内毒素对小鼠饮水量和体重的影响。
J Exp Med. 1961 May 1;113(5):921-34. doi: 10.1084/jem.113.5.921.
10
The effect of variation in molecular weight on the antigenicity of dextran in man.分子量变化对人体内右旋糖酐抗原性的影响。
Arch Biochem Biophys. 1958 Dec;78(2):306-18. doi: 10.1016/0003-9861(58)90354-0.